OLEMA PHARMACEUTICALS

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2024 16:29:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

11 Mar 2024 16:03:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

06 Mar 2024 07:03:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences

06 Feb 2024 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 16:30:00 By Nasdaq GlobeNewswire

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

08 Jan 2024 08:12:48 By Nasdaq GlobeNewswire

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

05 Dec 2023 12:27:48 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2023 16:29:00 By Nasdaq GlobeNewswire

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

28 Nov 2023 17:10:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 Nov 2023 16:02:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Nov 2023 16:32:00 By Nasdaq GlobeNewswire

Olema Oncology to Participate in Upcoming Investor Conferences in November

01 Nov 2023 16:27:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

22 Oct 2023 02:55:00 By Nasdaq GlobeNewswire

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

17 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

16 Oct 2023 07:02:00 By Nasdaq GlobeNewswire

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

12 Oct 2023 07:01:00 By Nasdaq GlobeNewswire

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2023 16:30:00 By Nasdaq GlobeNewswire